Pharma International Company

What Pharma International Company does

Pharma International Company (PIC) is a branded generic pharmaceutical manufacturer founded in 1994 as a green-field plant in Amman, Jordan, with commercial operations beginning in 2001. The company is consolidated under Axantia, a holding company formed in 2014 and domiciled in the Dubai International Financial Centre (UAE), whose co-owners are Al-Faisaliah Group and Sana Investments (the latter succeeding the founding Abu Al-Haj family interest). PIC runs three manufacturing facilities across Jordan and Saudi Arabia, producing more than 200 branded generic products spanning cardiovascular, anti-infective, respiratory, central nervous system, metabolic, dermatological, and gastrointestinal therapeutic areas, with particular specialization in general formulations and cephalosporins in both oral and injectable dosage forms.

The company sits within the top 10 of MENA pharmaceutical manufacturers and distributes its portfolio across 19 countries spanning the Middle East and North Africa, sub-Saharan Africa, and the Commonwealth of Independent States. Its go-to-market operates through in-country distribution and pharmacy partners in each market rather than direct-to-patient sales, and it supplements organic portfolio growth with in-licensing and co-development deals. PIC expanded its Saudi footprint materially through the 2015 acquisition of Med City Pharma, supporting local manufacturing and registration in the kingdom.

The revenue model is a B2B branded-generics commercial model: PIC manufactures finished dosage forms, registers them in each target market, and sells to local pharmaceutical distributors and wholesalers, which in turn supply hospitals, pharmacies, and public tenders. Customer concentration is structurally diffuse at the end-patient level across therapeutic categories, but revenue is intermediated by a finite set of national distribution partners per market. Capital structure is anchored by the Axantia platform, with strategic shareholders (Al-Faisaliah Group, Sana Investments) providing both governance and Saudi regional access.

Name

Pharma International Company

Legal name

Axantia

Website

https://axantia.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Pharma International Company manufactures 200+ branded generic pharmaceuticals across seven therapeutic areas, including specialized cephalosporins, from three factories in Jordan and Saudi Arabia, distributing to 19 countries across MENA, Africa, and CIS as part of the Axantia holding platform.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Generic pharmaceuticals
• Branded generic medicines
• Pharmaceutical manufacturing
• Cephalosporin antibiotics
• Cardiovascular medications

Headquarters

HQ city

Amman

HQ country

Jordan

HQ region

Middle East

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Generic Pharmaceutical Products: Develops, manufactures, markets, and distributes branded generic pharmaceuticals and under-licensed products. Revenue is generated through the sale of generic medicines across therapeutic areas including tablets, capsules, injections, syrups, dry suspensions, suppositories, medicated shampoos, creams, ointments, and gels.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Pharma International Company (PIC) develops, manufactures, markets, and distributes a portfolio of over 200 branded generic pharmaceutical products across therapeutic classes including cardiovascular, anti-infective, respiratory, CNS, metabolic, dermatological, and gastrointestinal medications. Products are manufactured in multiple dosage forms (tablets, capsules, injections, syrups, dry suspensions, suppositories, medicated shampoos, creams, ointments, gels) at three factories in Jordan and Saudi Arabia, and distributed across 19 countries in the Middle East, Africa, and CIS regions.

Product overview

Pharma International Company (PIC), based in Amman, Jordan, is a pharmaceutical manufacturing company established in 1994 that officially began operations in 2001. PIC develops, manufactures, markets, and distributes branded generic medications across the MENA region. The company operates through Axantia as its parent company and operates 3 manufacturing factories in Jordan and Saudi Arabia. With a product portfolio exceeding 200 products covering key therapeutic classes including cardiovascular (Adams, Amstar, Carvidol, Simvatin), anti-infective (Anabact, Axomax, Cefix), respiratory (Aeriallerg, Alivio, Lukast, Polmena, Zephyr), diabetes/metabolic (Diostar, Glymet), and gastrointestinal (Pumpinox) medications. Products are manufactured in multiple dosage forms: tablets, capsules, injections, syrups, dry suspensions, suppositories, medicated shampoos, creams, ointments, and gels. PIC's manufacturing capabilities span General Formulations and Cephalosporins (oral and injectable).

Differentiator

Problem solved

Functional benefit

Products and services

• Adams (Amlodipine) Calcium channel blocker for cardiovascular conditions, available in 5mg, 10mg, and 20mg film-coated tablet formulations.
• Aeriallerg Anti-allergic medication available as 0.5mg/ml syrup and 5mg film-coated tablets.
• Alivio Nasal spray medication at 0.05% concentration for nasal conditions.
• Amstar Combination medication with amlodipine/valsartan in 160/10mg and 160/5mg film-coated tablet formulations for cardiovascular conditions.
• Anabact Antibiotic powder for injection available in 1g and 2g formulations for IM, IV, and IM/IV administration.
• Axomax Antibiotic powder for IM/IV injection in 500mg and 1g formulations.
• Carvidol Beta-blocker medication in tablet form with 6.25mg, 12.5mg, and 25mg dosages for cardiovascular conditions.
• Cefix Cephalosporin antibiotic available as dry suspension (100mg/5ml) and hard gelatin capsules (200mg, 400mg); also marketed under Maxime and Midixime brands.
• Diostar DPP-4 inhibitor medication (linagliptin) for diabetes management available in 80mg and 160mg film-coated tablets, with Diostar Plus combination products.
• Glymet Metformin-based diabetes medication available in 500mg and 850mg film-coated tablets, with extended-release Glymet XR variants (500mg, 750mg, 1000mg).
• Lukast Montelukast medication for respiratory conditions available as 10mg film-coated tablets and 4mg/5mg chewable tablets.
• Polmena Inhalation suspension at 0.5mg/ml concentration for respiratory therapy.
• Pumpinox Proton pump inhibitor available as enteric-coated tablets in 20mg and 40mg doses for gastrointestinal conditions.
• Simvatin Statin medication for cholesterol management available in 10mg, 20mg, and 40mg film-coated tablets.
• Zephyr Inhalation suspension at 0.5mg/ml concentration for respiratory therapy.
• Pharma International Company (PIC) Product Portfolio Branded generic pharmaceutical product portfolio of over 200 products covering key therapeutic classes including cardiovascular, anti-infective, respiratory, CNS, metabolic, dermatological, and gastrointestinal medications, distributed across the Middle East and Africa region.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Various Pharmaceutical CompaniesminorStrategic or Co-development PartnerAxantia partners with select pharmaceutical companies for MA acquisitions, in/out licensing, and co-development arrangements to provide streamlined access to finished products across the MENA region.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Tabuk Pharmaceuticals: Saudi Arabia-based pharmaceutical manufacturer producing generics across multiple therapeutic categories. Comparable as a regional generics manufacturer operating in the same primary market that Axantia's MCP subsidiary serves.
• Eva Pharma: Egypt-based pharmaceutical manufacturer with growing MENA/Africa export presence across generics and specialty categories. Comparable as a regionally focused generic manufacturer expanding across similar emerging markets.
• Jamjoom Pharma: Saudi-based pharmaceutical manufacturer with branded generics across MENA. Comparable as a regional peer targeting the same Saudi healthcare localization opportunity.
• Gulf Pharmaceutical Industries (Julphar): UAE-based generic pharmaceutical manufacturer producing across multiple dosage forms for MENA markets. Comparable as a MENA-anchored generics manufacturer with regional manufacturing and distribution, though headquartered in the same Gulf region as Axantia's holding company.
• Hikma Pharmaceuticals: Jordan-headquartered multinational generic and specialty pharmaceutical manufacturer with deep MENA presence and broad product portfolio. Most directly comparable peer given shared Jordanian origin, branded-generic model, and MENA distribution footprint.
• EIPICO (Egyptian International Pharmaceutical Industries Company): One of the largest Egyptian pharmaceutical manufacturers producing generics for MENA and African markets. Comparable as a regional generic manufacturer serving overlapping patient populations and therapeutic categories.
• Aspen Pharmacare: South African-headquartered generic pharmaceutical manufacturer with strong African and emerging-market distribution. Comparable through its emerging-market generics model and therapeutic-category breadth overlapping with PIC's portfolio.
• SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances): Leading Saudi pharmaceutical manufacturer of branded generics and under-licensed products. Comparable as a top-tier MENA generics manufacturer with similar portfolio breadth and Saudi manufacturing base.

Broad incumbents

• Cipla: Indian-headquartered global generic pharmaceutical manufacturer with established MENA and African market presence. Comparable through its generics portfolio and emerging-market distribution model, though operating at materially larger scale.
• Dr. Reddy's Laboratories: Indian-headquartered global generic manufacturer with significant emerging-market footprint including MENA. Comparable in generics product mix and emerging-market distribution, though at substantially larger global scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/pharma-international

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharma International Company